Dalton Pharma Services announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology. The sterile fill line is fully integrated with a new cGMP lyophilizer, providing complete sterile finished dosage form manufacturing capabilities for customers.
TORONTO, Feb. 16, 2023 /PRNewswire/ -- Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology. The sterile fill line is fully integrated with a new cGMP lyophilizer, providing complete sterile finished dosage form manufacturing capabilities for customers.
Dalton Pharma Services has announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology. The sterile fill line is fully integrated with a new cGMP lyophilizer, providing complete sterile finished dosage form manufacturing capabilities for customers.
Dalton Pharma Services, a North-American contract drug manufacturing organization has added instrumentation to perform extractables and leachables determining on container closure systems.
Tetra Bio-Pharma Inc. has awarded the contract for the manufacturing of its active pharmaceutical ingredient (API), HU-308, and of the intravenous, sterile, finished drug product ARDS-003 to Dalton Pharma Services
Dalton Pharma Services has partnered with the University of Saskatchewan’s Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO-InterVac) in their effort to develop a vaccine for COVID-19. Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.
The U.S. FDA completed a PAI inspection of Dalton Pharma Services’ Health-Canada licensed manufacturing facility in Canada, in January 2019. This inspection paves way for Dalton to manufacture commercial API products for U.S. distribution.
TORONTO, Nov. 22, 2018 /PRNewswire-PRWeb/ -- Dalton Pharma Services, a leading North American pharmaceutical cGMP CDMO, is pleased to announce its drug development and manufacturing services agreement with ExCellThera Inc, an innovative biotechnology company focused on delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use.